SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy.

Moon, RJ; Harvey, NC; Cooper, C; D'Angelo, S; Crozier, SR; Inskip, HM; Schoenmakers, I; Prentice, A; Arden, NK; Bishop, NJ; et al. Moon, RJ; Harvey, NC; Cooper, C; D'Angelo, S; Crozier, SR; Inskip, HM; Schoenmakers, I; Prentice, A; Arden, NK; Bishop, NJ; Carr, A; Dennison, EM; Eastell, R; Fraser, R; Gandhi, SV; Godfrey, KM; Kennedy, S; Mughal, MZ; Papageorghiou, AT; Reid, DM; Robinson, SM; Javaid, MK (2016) Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy. J Clin Endocrinol Metab, 101 (12). pp. 5012-5020. ISSN 1945-7197 https://doi.org/10.1210/jc.2016-2869
SGUL Authors: Papageorghiou, Aris

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (522kB) | Preview

Abstract

CONTEXT: Current approaches to antenatal vitamin D supplementation do not account for interindividual differences in 25-hydroxyvitamin D (25(OH)D) response. OBJECTIVE: We assessed which maternal and environmental characteristics were associated with 25(OH)D after supplementation with cholecalciferol. DESIGN: Within-randomization-group analysis of participants in the Maternal Vitamin D Osteoporosis Study trial of vitamin D supplementation in pregnancy. SETTING: Hospital antenatal clinics. PARTICIPANTS: A total of 829 pregnant women (422 placebo, 407 cholecalciferol). At 14 and 34 weeks of gestation, maternal anthropometry, health, and lifestyle were assessed and 25(OH)D measured. Compliance was determined using pill counts at 19 and 34 weeks. INTERVENTIONS: 1000 IU/d of cholecalciferol or matched placebo from 14 weeks of gestation until delivery. MAIN OUTCOME MEASURE: 25(OH)D at 34 weeks, measured in a single batch (Diasorin Liaison). RESULTS: 25(OH)D at 34 weeks of gestation was higher in the women randomized to vitamin D (mean [SD], 67.7 [21.3] nmol/L) compared with placebo (43.1 [22.5] nmol/L; P < .001). In women randomized to cholecalciferol, higher pregnancy weight gain from 14 to 34 weeks of gestation (kg) (β = -0.81 [95% confidence interval -1.39, -0.22]), lower compliance with study medication (%) (β = -0.28 [-0.072, -0.48]), lower early pregnancy 25(OH)D (nmol/L) (β = 0.28 [0.16, 0.40]), and delivery in the winter vs the summer (β = -10.5 [-6.4, -14.6]) were independently associated with lower 25(OH)D at 34 weeks of gestation. CONCLUSIONS: Women who gained more weight during pregnancy had lower 25(OH)D in early pregnancy and delivered in winter achieved a lower 25(OH)D in late pregnancy when supplemented with 1000 IU/d cholecalciferol. Future studies should aim to determine appropriate doses to enable consistent repletion of 25(OH)D during pregnancy.

Item Type: Article
Additional Information: This article has been published under the terms of the Creative Commons Attribution License(CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).
Keywords: Adult, Cholecalciferol, Double-Blind Method, Female, Humans, Outcome Assessment (Health Care), Pregnancy, Pregnancy Trimesters, Seasons, Vitamin D, Vitamins, Weight Gain, Young Adult, Endocrinology & Metabolism, 1103 Clinical Sciences, 1114 Paediatrics And Reproductive Medicine
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: J Clin Endocrinol Metab
ISSN: 1945-7197
Language: eng
Dates:
DateEvent
1 December 2016Published
28 October 2016Published Online
3 October 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MRC_MC_U147574234Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_U147574212Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_UP_A620_1017Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
17702Arthritis Research UKhttp://dx.doi.org/10.13039/501100000341
MRC_MC_UP_A620_1014Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_UU_12011/4Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
ARC_19583Arthritis Research UKhttp://dx.doi.org/10.13039/501100000341
ARC_21231Arthritis Research UKhttp://dx.doi.org/10.13039/501100000341
U105960371Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_U147574222Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_U147585819Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_U147574226Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_UU_12011/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC_MC_U147574237Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
DH_HTA/10/33/04Department of Healthhttp://dx.doi.org/10.13039/501100000276
4050502589Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
PubMed ID: 27788053
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109169
Publisher's version: https://doi.org/10.1210/jc.2016-2869

Actions (login required)

Edit Item Edit Item